News Column

Baxter Reports Fourth Quarter 2013 Financial Results in Line with Expectations

January 23, 2014

Sales Growth of 16 Percent Driven by Strong Demand for Hemophilia Therapies, Medical Products & Gambro Acquisition Company Provides 2014 Financial Outlook, Advances New Product Pipeline & Collaborations DEERFIELD, Ill. --(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX) today announced financial results for the fourth quarter of 2013, and provided its financial outlook for the first quarter and full-year 2014. For the fourth quarter, Baxter reported net income of $326 million and earnings per diluted share of $0.59 , compared to net income of $494 million and earnings per diluted share of $0.89 in the same period last year. These results include after-tax special items totaling $366 million (or $0.67 per diluted share), primarily for costs associated with Baxter’s acquisition of Gambro, business optimization programs and recent collaborations with Coherus Biosciences and Cell Therapeutics, Inc. Fourth quarter 2012 results included after-tax special items of $206 million (or $0.37 per diluted share). On an adjusted basis, excluding special items, Baxter’s net income totaled $692 million , or $1.26 per diluted share, in line with the company’s previously-issued earnings guidance. Worldwide sales totaled $4.4 billion and increased 16 percent from prior-year levels. Excluding the contribution of Gambro revenues in the quarter, Baxter’s sales increased 5 percent to $4.0 billion (or 6 percent excluding the impact of foreign currency). Sales within the United States totaled $1.8 billion and advanced 13 percent, and international sales of $2.6 billion increased 19 percent (or 20 percent excluding the impact of foreign currency). BioScience revenues of $1.8 billion grew 5 percent from the prior-year period (or 6 percent excluding the impact of foreign currency), driven primarily by double-digit growth and solid demand for the company’s hemophilia therapies, including ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] and FEIBA (an inhibitor therapy) in the United States and Europe , as well as for biosurgery products. Medical Products sales of $2.6 billion increased 25 percent from the prior-year period (or 27 percent excluding the impact of foreign currency), and included revenues associated with the Gambro acquisition of $413 million . Excluding foreign currency and the contribution from the acquisition, Medical Products sales grew 7 percent, driven by strong growth across the entire business portfolio. Full-Year Results Baxter’s net income totaled $2.0 billion , or $3.66 per diluted share in 2013. Excluding special items, Baxter’s adjusted net income increased 2 percent to $2.6 billion , and earnings per diluted share of $4.67 advanced 3 percent. Baxter’s worldwide sales in 2013 totaled $15.3 billion and rose 8 percent. Excluding revenues of $513 million associated with the Gambro acquisition, Baxter’s revenues increased 4 percent to $14.7 billion . BioScience sales of $6.6 billion advanced 5 percent (or 6 percent excluding the impact of foreign currency), while Medical Products sales of $8.7 billion grew 9 percent from the prior-year period. Excluding revenues associated with the Gambro acquisition, Medical Products sales increased 3 percent (or 4 percent excluding the impact of foreign currency) on a full-year basis. During 2013, Baxter generated cash flows from operations of approximately $3.2 billion and returned significant value to shareholders. Baxter returned more than $1.9 billion to shareholders during the year, through share repurchases of $913 million (or approximately 13 million shares) and dividends totaling more than $1.0 billion , reflecting a 27 percent increase in dividend payments versus the prior year. ''We continue to meet our financial objectives while navigating a challenging and complex macro-environment,'' said Robert L. Parkinson , Jr., chairman and chief executive officer. ''We remain focused on the company’s strategic priorities of advancing the new product pipeline, investing in future growth opportunities, and strengthening our operational execution, which will result in enhanced value for patients, healthcare providers and shareholders.'' 2013 Highlights In 2013, Baxter continued to transform its new product pipeline into a robust portfolio of products and therapies that improve the quality of care and address key, high-potential areas of unmet medical need, while also expanding its business portfolio. This is evidenced by: Increased spending in research and development by 8 percent, investing more than $1.2 billion for both internal programs and new collaborations, a record level for the company. Achieving a number of clinical and regulatory milestones, including the progression of several key programs into late stage clinical trials; completion of regulatory submissions for new hemophilia and immune globulin products; and approval of an array of new indications and treatments for end-stage renal disease and hemophilia, as well as immune globulin, biosurgery and parenteral nutrition products. Establishing several collaborations that leverage Baxter’s proven expertise and extend the company’s pipeline in new therapeutic areas including hematology, oncology and immunology. Enhancing Baxter’s global leadership in renal therapies with the acquisition of Gambro AB, providing the company with a comprehensive product and therapies portfolio to meet the needs of patients, as well as a number of long-term growth opportunities. ''We are building upon the proven expertise and leadership we have across a number of therapeutic areas by capitalizing on our significant global presence and differentiated brands, pursuing innovation and establishing a robust new product pipeline, and improving access and standards of care around the world while enhancing patient outcomes,'' said Parkinson. Fourth Quarter Highlights Momentum accelerated in the fourth quarter as Baxter advanced its late-stage pipeline with a number of regulatory filings, product approvals, and collaborations. Highlights include: Submission of an amended biologics license application (BLA) to the United States Food and Drug Administration (FDA) to re-initiate the review process for approval of HyQvia [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase], a subcutaneous infusion for the treatment of adult patients with primary immunodeficiency (PI). HyQvia was approved and then launched in a number of European countries in the second half of 2013. Conclusion of enrollment in the Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile. BAX 855 was designed based on the full-length ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] molecule, and modified with PEGylation technology designed to extend its duration of activity in the body. To date, no inhibitors or safety issues have been reported in the study. BLA submission to the FDA for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A. OBI-1 has been granted orphan-drug designation by the FDA , and the application has also been granted a priority review, which is intended to expedite the review process of drug candidates with the potential to fulfill an unmet medical need. Submission of an application to the FDA for a pediatric indication for RIXUBIS [Coagulation Factor IX (Recombinant)] to treat hemophilia B. The company has also submitted a marketing authorization application (MAA) for the treatment of patients of all ages in Japan and to the European Medicines Agency (EMA). RIXUBIS was approved in the United States for adults with hemophilia B earlier in 2013. FDA approval of Baxter’s FEIBA [ Anti-Inhibitor Coagulant Complex ], the first and only treatment in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors. The presence of an inhibitor makes response to treatment more challenging, and patients with inhibitors have an increased risk of developing complications. In clinical trials, FEIBA prophylactic regimen showed a 72 percent reduction in median annual bleed rate (ABR) compared to treatment with an on-demand regimen. FEIBA is approved in more than 60 countries worldwide and is indicated for prophylaxis in more than 40 countries. CE marking in Europe for the VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy. VIVIA is designed with the potential to deliver enhanced clinical outcomes and greater patient convenience, and provides a number of unique safety features, wireless connectivity, an integrated water system and extended-use consumables. Baxter will introduce VIVIA in a limited number of European dialysis clinics in 2014 and expand the launch to other European countries in 2015. Execution of an exclusive worldwide licensing agreement with Cell Therapeutics, Inc. (CTI), to develop and commercialize pacritinib, a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder. Under the terms of the agreement, Baxter gains exclusive commercialization rights for all indications for pacritinib outside the United States and Baxter and CTI will jointly commercialize pacritinib in the United States . Outlook for First Quarter and Full-Year 2014 Baxter also announced today its outlook for the first quarter and full-year 2014. Baxter expects sales growth for full-year 2014 of 9 to 10 percent, before the impact of foreign exchange. Also, for the full year, Baxter expects earnings, before special items, of $5.05 to $5.25 per diluted share and cash flows from operations of approximately $3.5 billion . The 2014 earnings guidance excludes approximately $0.25 per diluted share of intangible asset amortization expense. Reconciling for the inclusion of intangible asset amortization results in GAAP (Generally Accepted Accounting Principles) earnings of $4.80 to $5.00 per diluted share, before other special items. Historical financial results (restated for the exclusion of intangible amortization) are available on the Investor Relations page of Baxter’s website at www.baxter.com . For the first quarter of 2014, the company expects sales growth of approximately 13 to 14 percent, excluding the impact of foreign currency. Baxter expects earnings, before special items, of $1.06 to $1.09 per diluted share in the first quarter (or GAAP earnings of $1.00 to $1.03 per diluted share including approximately $0.06 per diluted share of intangible asset amortization expense). A webcast of Baxter’s fourth quarter conference call for investors can be accessed live from a link on the company's website at www.baxter.com beginning at 7:30 a.m. CST on January 23, 2014 . Please visit www.baxter.com for more information regarding this and future investor events and webcasts. Baxter International Inc. , through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. This release includes forward-looking statements concerning the company’s financial results, business development activities, R&D pipeline and outlook for 2014. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance of risks for new and existing products, such as ADVATE, and other technologies; future actions of regulatory bodies and other governmental authorities that could delay, limit or suspend product development, manufacturing or sales or result in sanctions; product quality or patient safety concerns leading to product recalls, withdrawals, launch delays, litigation, or declining sales; future actions of governmental authorities and other third parties as U.S. healthcare reform legislation and other austerity measures are implemented globally; additional legislation, regulation and other governmental pressures, which may affect pricing, taxation, reimbursement and rebate policies of government agencies and private payers or other elements of the company’s business; product development risks, including satisfactory clinical performance; the company's ability to realize the anticipated benefits from its business development and R&D activities, including the ability to successfully integrate the Gambro acquisition; inventory reductions or fluctuations in buying patterns by wholesalers or distributors; the impact of geographic and product mix on the company's sales; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; the availability of acceptable raw materials and component supply; fluctuations in supply and demand and the pricing of plasma-based therapies; the ability to enforce company patents; patents of third parties preventing or restricting the company’s manufacture, sale or use of affected products or technology; the impact of global economic conditions on Baxter and its customers, including foreign governments in certain countries in which the company operates; foreign currency fluctuations and other risks identified in the company’s most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements. Financial schedules are attached to this release and available on the company’s website. BAXTER INTERNATIONAL INC. Consolidated Statements of Income Three Months Ended December 31, 2013 and 2012 (unaudited) (in millions, except per share and percentage data) Three Months Ended December 31 , 2013 2012 Change NET SALES $4,368 $3,753 16% COST OF SALES 2,414 1,848 31% GROSS MARGIN 1,954 1,905 3% % of Net Sales 44.7% 50.8% (6.1 pts) MARKETING AND ADMINISTRATIVE EXPENSES 1,064 1,040 2% % of Net Sales 24.4% 27.7% (3.3 pts) RESEARCH AND DEVELOPMENT EXPENSES 437 291 50% % of Net Sales 10.0% 7.8% 2.2 pts NET INTEREST EXPENSE 41 22 86% OTHER INCOME, NET (19) (22) N/M PRE-TAX INCOME 431 574 (25%) INCOME TAX EXPENSE 105 80 31% % of Pre-Tax Income 24.4% 13.9% 10.5 pts NET INCOME $326 $494 (34%) BASIC EPS $0.60 $0.90 (33%) DILUTED EPS $0.59 $0.89 (34%) WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic 543 548 Diluted 548 555 ADJUSTED PRE-TAX INCOME (excluding special items) $902 A $894 A 1% ADJUSTED NET INCOME (excluding special items) $692 A $700 A (1%) ADJUSTED DILUTED EPS (excluding special items) $1.26 A $1.26 A 0% A Refer to page 10 for a description of the adjustments and a reconciliation to generally accepted accounting principles (GAAP) measures. BAXTER INTERNATIONAL INC. Note to Consolidated Statements of Income Three Months Ended December 31, 2013 and 2012 Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures (unaudited) (in millions, except per share and percentage data) The company's GAAP results for the three months ended December 31, 2013 and 2012 included special items which impacted the GAAP measures as follows: Three Months Ended December 31 , 2013 2012 Change Gross Margin $1,954 $1,905 3% Gambro acquisition and integration items 1 47 - Business optimization items 2 145 62 Product-related items 3 17 - Adjusted Gross Margin $2,163 $1,967 10% % of Net Sales 49.5% 52.4% (2.9 pts) Marketing and Administrative Expenses $1,064 $1,040 2% Gambro acquisition and integration items 1 (42) - Business optimization items 2 (82) (60) Pension settlement items 5 - (170) Adjusted Marketing and Administrative Expenses $940 $810 16% % of Net Sales 21.5% 21.6% (0.1 pts) Research and Development Expenses $437 $291 50% Business development items 4 (78) - Business optimization items 2 (55) (28) Adjusted Research and Development Expenses $304 $263 16% % of Net Sales 7.0% 7.0% 0 pts Other Income, Net $(19) $(22) N/M Gambro acquisition and integration items 1 (5) - Adjusted Other Income, Net $(24) $(22) N/M Pre-Tax Income $431 $574 (25%) Impact of special items 471 320 Adjusted Pre-Tax Income $902 $894 1% Income Tax Expense $105 $80 31% Impact of special items 105 114 Adjusted Income Tax Expense $210 $194 8% % of Adjusted Pre-Tax Income 23.3% 21.7% 1.6 pts Net Income $326 $494 (34%) Impact of special items 366 206 Adjusted Net Income $692 $700 (1%) Diluted EPS $0.59 $0.89 (34%) Impact of special items 0.67 0.37 Adjusted Diluted EPS $1.26 $1.26 0% WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Diluted 548 555 1 Cost of sales, marketing and administrative expenses and other income, net in 2013 included total charges of $94 million ( $79 million , or $0.14 per diluted share, on an after-tax basis) principally related to the acquisition and integration of Gambro AB (Gambro). 2 The company undertook business optimization initiatives resulting in charges totaling $282 million ( $212 million , or $0.39 per diluted share, on an after-tax basis) and $150 million ( $101 million , or $0.18 per diluted share, on an after-tax basis) in 2013 and 2012, respectively. 3 Cost of sales in 2013 included total charges of $17 million ( $10 million , or $0.02 per diluted share, on an after-tax basis) principally related to remediation efforts associated with modifications to the SIGMA Spectrum Infusion Pump in conjunction with re-filing for 510(k) clearance. 4 The company incurred business development charges in 2013 totaling $78 million ( $65 million , or $0.12 per diluted share, on an after-tax basis) which related to R&D charges of $45 million associated with the company's collaboration with Coherus Biosciences, Inc. (Coherus) and $33 million associated with the company's collaboration with Cell Therapeutics, Inc. (Cell Therapeutics). 5 Marketing and administrative expenses in 2012 included a charge totaling $170 million ( $105 million , or $0.19 per diluted share, on an after-tax basis) primarily related to the settlement of certain pension obligations in the United States . For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release. BAXTER INTERNATIONAL INC. Consolidated Statements of Income Twelve Months Ended December 31, 2013 and 2012 (unaudited) (in millions, except per share and percentage data) Twelve Months Ended December 31 , 2013 2012 Change NET SALES $15,259 $14,190 8% COST OF SALES 7,664 6,889 11% GROSS MARGIN 7,595 7,301 4% % of Net Sales 49.8% 51.5% (1.7 pts) MARKETING AND ADMINISTRATIVE EXPENSES 3,681 3,324 11% % of Net Sales 24.1% 23.4% 0.7 pts RESEARCH AND DEVELOPMENT EXPENSES 1,246 1,156 8% % of Net Sales 8.2% 8.1% 0.1 pts NET INTEREST EXPENSE 128 87 47% OTHER INCOME, NET (9) (155) N/M PRE-TAX INCOME 2,549 2,889 (12%) INCOME TAX EXPENSE 537 563 (5%) % of Pre-Tax Income 21.1% 19.5% 1.6 pts NET INCOME $2,012 $2,326 (13%) BASIC EPS $3.70 $4.22 (12%) DILUTED EPS $3.66 $4.18 (12%) WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic 543 551 Diluted 549 556 ADJUSTED PRE-TAX INCOME (excluding special items) $3,293 A $3,223 A 2% ADJUSTED NET INCOME (excluding special items) $2,567 A $2,516 A 2% ADJUSTED DILUTED EPS (excluding special items) $4.67 A $4.53 A 3% A Refer to page 12 for a description of the adjustments and a reconciliation to GAAP measures. BAXTER INTERNATIONAL INC. Note to Consolidated Statements of Income Twelve Months Ended December 31, 2013 and 2012 Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures (unaudited) (in millions, except per share and percentage data) The company's GAAP results for the twelve months ended December 31, 2013 and 2012 included special items which impacted the GAAP measures as follows: Twelve Months Ended December 31 , 2013 2012 Change Gross Margin $7,595 $7,301 4% Gambro acquisition and integration items 1 62 - Currency-related items 2 1 - Business optimization items 3 125 62 Product-related items 4 17 - Business development items 6 - 6 Reserve adjustments 7 - (23) Adjusted Gross Margin $7,800 $7,346 6% % of Net Sales 51.1% 51.8% (0.7 pts) Marketing and Administrative Expenses $3,681 $3,324 11% Gambro acquisition and integration items 1 (115) - Business optimization items 3 (82) (60) Tax and legal reserves 5 (124) - Business development items 6 - (9) Pension settlement items 8 - (170) Adjusted Marketing and Administrative Expenses $3,360 $3,085 9% % of Net Sales 22.0% 21.7% 0.3 pts Research and Development Expenses $1,246 $1,156 8% Business optimization items 3 (73) (28) Business development items 6 (103) (113) Adjusted Research and Development Expenses $1,070 $1,015 5% % of Net Sales 7.0% 7.2% (0.2 pts) Other Income, Net $(9) $(155) N/M Gambro acquisition and integration items 1 (15) - Currency-related items 2 (62) - Tax and legal reserves 5 35 - Reserve adjustments 7 - 91 Adjusted Other Income, Net $(51) $(64) N/M Pre-Tax Income $2,549 $2,889 (12%) Impact of special items 744 334 Adjusted Pre-Tax Income $3,293 $3,223 2% Income Tax Expense $537 $563 (5%) Impact of special items 189 144 Adjusted Income Tax Expense $726 $707 3% % of Adjusted Pre-Tax Income 22.0% 21.9% 0.1 pts Net Income $2,012 $2,326 (13%) Impact of special items 555 190 Adjusted Net Income $2,567 $2,516 2% Diluted EPS $3.66 $4.18 (12%) Impact of special items 1.01 0.35 Adjusted Diluted EPS $4.67 $4.53 3% WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Diluted 549 556 1 Cost of sales, marketing and administrative expenses and other income, net in 2013 included total charges of $192 million ( $157 million , or $0.28 per diluted share, on an after-tax basis) principally related to the acquisition and integration of Gambro. 2 Cost of sales and other income, net in 2013 included a charge of $11 million ( $7 million , or $0.01 per diluted share, on an after-tax basis) related to the Venezuelan currency devaluation announced by the government of Venezuela in February 2013 . Additionally, other income, net in 2013 included a net loss of $52 million ( $33 million , or $0.06 per diluted share, on an after-tax basis) principally related to the company's derivative instruments used to hedge the anticipated foreign currency cash outflows for the Gambro acquisition. 3 The company undertook business optimization initiatives resulting in a net charge of $280 million ( $212 million , or $0.39 per diluted share, on an after-tax basis) in 2013, which included a net benefit of $2 million in the second quarter of 2013 associated with a benefit of $20 million related to an adjustment to a previous business optimization reserve and a charge of $18 million primarily related to the discontinuation of the company's Alzheimer's disease program. In 2012, the company had charges totaling $150 million ( $101 million , or $0.18 per diluted share, on an after-tax basis) related to business optimization initiatives. 4 Cost of sales in 2013 included total charges of $17 million ( $10 million , or $0.02 per diluted share, on an after-tax basis) principally related to remediation efforts associated with modifications to the SIGMA Spectrum Infusion Pump in conjunction with re-filing for 510(k) clearance. 5 Marketing and administrative expenses in 2013 included charges totaling $124 million ( $95 million , or $0.17 per diluted share, on an after-tax basis) related to tax and legal reserves associated with VAT matters in Turkey and existing class-action and other related litigation, including litigation fees. Income tax expense in 2013 included a net benefit of $6 million ( $0.01 per diluted share) related to uncertain tax positions in Switzerland and Turkey . Other income, net in 2013 included the offsetting impact of $35 million ( $0.06 per diluted share) in noncontrolling interest for the VAT and tax items above associated with the company's non-wholly owned subsidiary in Turkey . 6 The company incurred business development charges in 2013 totaling $103 million ( $82 million , or $0.15 per diluted share, on an after-tax basis) which related to R&D charges of $45 million associated with the company's collaboration with Coherus, $33 million associated with the company's collaboration with Cell Therapeutics, and $25 million related to the company's collaboration agreement with JW Holdings. In 2012, the company incurred business development charges totaling $128 million ( $102 million , or $0.19 per diluted share, on an after-tax basis) which principally related to R&D charges of $33 million associated with the company’s global collaboration with Momenta Pharmaceuticals, Inc. (Momenta), $30 million associated with the company's global collaboration with Chatham Therapeutics, LLC (Chatham), and $50 million associated with the company's licensing agreement with Onconova. 7 Cost of sales in 2012 included a net benefit of $23 million ( $27 million , or $0.05 per diluted share, on an after-tax basis) primarily related to an adjustment to the COLLEAGUE infusion pump reserves as the company substantially completed its recall activities in the United States . Other income, net in 2012 included a benefit of $91 million , or $0.16 per diluted share, consisting of gains of $53 million and $38 million for the reduction of certain contingent payment liabilities related to the prior acquisitions of Prism Pharmaceuticals, Inc. and ApaTech Limited , respectively, for which there was no tax expense recognized. 8 Marketing and administrative expenses in 2012 included a charge totaling $170 million ( $105 million , or $0.19 per diluted share, on an after-tax basis) primarily related to the settlement of certain pension obligations in the United States . For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release. BAXTER INTERNATIONAL INC. Reconciliation of GAAP to Non-GAAP Measures - Adjusted Results Excluding Amortization Expense 1 (unaudited) (in millions, except per share and percentage data) Three Months Ended Twelve Months Ended March 31 , June 30 , September 30 , December 31 , December 31 , 2013 2013 2013 2013 2013 Gross Margin $1,756 $1,939 $1,946 $1,954 $7,595 Impact of special items 1 (20) 15 209 205 Adjusted Gross Margin $1,757 $1,919 $1,961 $2,163 $7,800 Intangible asset amortization expense 25 25 34 46 130 Adjusted Gross Margin, excluding amortization expense $1,782 $1,944 $1,995 $2,209 $7,930 Pre-Tax Income $693 $743 $682 $431 $2,549 Impact of special items 45 76 152 471 744 Adjusted Pre-Tax Income $738 $819 $834 $902 $3,293 Intangible asset amortization expense 25 25 34 46 130 Adjusted Pre-Tax Income, excluding amortization expense $763 $844 $868 $948 $3,423 Income Tax Expense $141 $153 $138 $105 $537 Impact of special items 16 27 41 105 189 Adjusted Income Tax Expense $157 $180 $179 $210 $726 Intangible asset amortization expense 2 5 5 7 11 28 Adjusted Income Tax Expense, excluding amortization expense $162 $185 $186 $221 $754 % of Adjusted Pre-Tax Income 21.3% 22.0% 21.5% 23.3% 22.0% Net Income $552 $590 $544 $326 $2,012 Impact of special items 29 49 111 366 555 Adjusted Net Income $581 $639 $655 $692 $2,567 Intangible asset amortization expense 20 20 27 35 102 Adjusted Net Income, excluding amortization expense $601 $659 $682 $727 $2,669 Diluted EPS $1.00 $1.07 $0.99 $0.59 $3.66 Impact of special items 0.05 0.09 0.20 0.67 1.01 Adjusted Diluted EPS $1.05 $1.16 $1.19 $1.26 $4.67 Intangible asset amortization expense 0.04 0.04 0.05 0.06 0.19 Adjusted Diluted EPS, excluding amortization expense $1.09 $1.20 $1.24 $1.32 $4.86 WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Diluted 551 549 549 548 549 1 Reconciliation of historical financial results, on a reported and adjusted basis, to Baxter's new non-GAAP presentation of adjusted results excluding amortization expense. 2 The company's overall effective tax rate has been used to determine the tax effect of intangible asset amortization expense. For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release. BAXTER INTERNATIONAL INC. Cash Flows from Operations and Changes in Net Debt (unaudited) ($ in millions) Cash Flows from Operations (Brackets denote cash outflows) Three Months Ended Twelve Months Ended December 31 , December 31 , 2013 2012 2013 2012 Net income $326 $494 $2,012 $2,326 Adjustments Depreciation and amortization 250 178 823 712 Deferred income taxes (309) (214) (224) (17) Stock compensation 39 33 150 130 Realized excess tax benefits from stock issued under employee benefit plans (2) (10) (34) (24) Business optimization items 282 150 282 150 Other 80 5 82 (42) Changes in balance sheet items Accounts and other current receivables, net (106) (113) (36) (41) Inventories 101 7 (311) (129) Accounts payable and accrued liabilities 405 300 349 18 Business optimization and infusion pump payments (44) (57) (125) (283) Other 61 172 230 306 Cash flows from operations $1,083 $945 $3,198 $3,106 Changes in Net Debt Increase (decrease) Three Months Ended Twelve Months Ended December 31 , December 31 , 2013 2012 2013 2012 Net debt, beginning of period A $6,690 $2,756 $2,660 $2,290 Cash flows from operations (1,083) (945) (3,198) (3,106) Capital expenditures 488 399 1,525 1,161 Dividends 266 246 1,023 804 Proceeds from stock issued under employee benefit plans (38) (195) (474) (488) Purchases of treasury stock 50 415 913 1,480 Acquisitions and investments 79 20 3,851 605 Sales of investments and other investing activities - (21) (14) (107) Payment of assumed Gambro debt - - 221 - Other, including the effect of exchange rate changes (19) (15) (74) 21 (Decrease) increase in net debt (257) (96) 3,773 370 Net debt, December 31 A $6,433 $2,660 $6,433 $2,660 Key statistics, December 31 : Days sales outstanding 55.9 B 53.3 55.9 B 53.3 Inventory turns 2.7 2.5 2.7 2.5 A Net debt is a non-GAAP measure, refer to page 16 for a description of net debt and a reconciliation to GAAP measures. B Includes the impact from the acquisition of Gambro in September 2013 . Excluding Gambro, the company's days sales outstanding was 52.5 days as of December 31, 2013 . BAXTER INTERNATIONAL INC. Total Debt to Net Debt Reconciliation (unaudited) ($ in millions) Total Debt to Net Debt Reconciliation A December 31 , September 30 , December 31 , September 30 , December 31 , 2013 2013 2012 2012 2011 Short-term debt $181 $42 $27 $16 $256 Current maturities of long-term debt and lease obligations 859 372 323 317 190 Long-term debt and lease obligations 8,126 8,652 5,580 5,614 4,749 Total debt 9,166 9,066 5,930 5,947 5,195 Less: Cash and equivalents (2,733) (2,376) (3,270) (3,191) (2,905) Total net debt $6,433 $6,690 $2,660 $2,756 $2,290 A Net debt represents the difference between total debt (defined as short-term debt, current maturities of long-term debt and lease obligations, and long-term debt and lease obligations as presented on the company's consolidated balance sheets) and cash and equivalents. For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release. BAXTER INTERNATIONAL INC. Net Sales Periods Ending December 31, 2013 and 2012 (unaudited) ($ in millions) Q4 Q4 % Growth @ % Growth @ YTD YTD % Growth @ % Growth @ 2013 2012 Actual Rates Constant Rates 2013 2012 Actual Rates Constant Rates BioScience United States $891 $825 8% 8% $3,277 $3,087 6% 6% International 885 862 3% 4% 3,287 3,150 4% 5% Total BioScience $1,776 $1,687 5% 6% $6,564 $6,237 5% 6% Medical Products United States $890 $747 19% 19% $3,174 $2,969 7% 7% International 1,702 1,319 29% 31% 5,521 4,984 11% 12% Total Medical Products 1 $2,592 $2,066 25% 27% $8,695 $7,953 9% 10% Baxter International Inc. United States $1,781 $1,572 13% 13% $6,451 $6,056 7% 7% International 2,587 2,181 19% 20% 8,808 8,134 8% 9% Total Baxter 1 $4,368 $3,753 16% 17% $15,259 $14,190 8% 8% 1 Includes Gambro net sales of $413 million in the fourth quarter of 2013 and $513 million since the acquisition of Gambro in September 2013 . Medical Products net sales excluding Gambro grew at 5% at actual rates and 7% at constant rates during the fourth quarter of 2013, and grew at 3% at actual rates and 4% at constant rates during the year ended December 31, 2013 . Total Baxter net sales grew at 5% at actual rates and 6% at constant rates during the fourth quarter of 2013, and grew at 4% at both actual and constant rates during the year ended December 31, 2013 . BAXTER INTERNATIONAL INC. Sales by Franchise 1 Periods Ending December 31, 2013 and 2012 (unaudited) ($ in millions) Q4 Q4 % Growth @ % Growth @ YTD YTD % Growth @ % Growth @ 2013 2012 Actual Rates Constant Rates 2013 2012 Actual Rates Constant Rates BioScience Hemophilia 2 $972 $887 10% 11% $3,437 $3,241 6% 7% BioTherapeutics 3 564 571 (1%) (2%) 2,118 2,069 2% 2% BioSurgery 4 194 180 8% 7% 717 673 7% 6% Vaccines 5 46 49 (6%) - % 292 254 15% 18% Total BioScience $1,776 $1,687 5% 6% $6,564 $6,237 5% 6% Medical Products Fluid Systems 6 $819 $775 6% 6% $3,106 $2,937 6% 6% Renal 7 1,099 675 63% 66% 3,089 2,527 22% 24% Specialty Pharmaceuticals 8 407 376 8% 8% 1,508 1,475 2% 2% BioPharma Solutions 9 267 240 11% 12% 992 1,014 (2%) (2%) Total Medical Products $2,592 $2,066 25% 27% $8,695 $7,953 9% 10% Total Baxter $4,368 $3,753 16% 17% $15,259 $14,190 8% 8% 1 Effective January 1, 2013 , Baxter has transitioned to a commercial franchise structure for reporting net sales. Prior period net sales have been reclassified to reflect the new commercial franchise structure. See Notes 2 - 9 below for a description of each commercial franchise. 2 Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE) and plasma-derived hemophilia products (primarily FVII, FVIII and FEIBA). Recombinant and plasma-based products were previously reported separately. 3 Includes sales of the company's liquid formulation of the antibody-replacement therapy immunoglobulin product (GAMMAGARD LIQUID) and other plasma-based therapies such as albumin and alpha-1 antitrypsin products. Antibody therapies and plasma-based products were previously reported separately. 4 Consists of biological products and delivery devices used for hemostasis, tissue sealing, adhesion reduction and hard tissue regeneration, as well as soft tissue repair and microsurgery products. 5 Consists of vaccines for seasonal and pandemic influenza, as well as meningitis C and tick-borne encephalitis. 6 Principally includes IV therapies, infusion pumps, administration sets and premixed drugs platforms. IV therapies were previously reported with nutrition products in IV Therapies, and Infusion Systems and Global Injectables were previously reported separately. 7 Consists of PD and HD therapies, and includes Gambro net sales of $413 million in the fourth quarter of 2013 and $513 million since the acquisition of Gambro in September 2013 . Renal sales excluding Gambro grew 2% at actual rates and 5% at constant rates during the fourth quarter of 2013, and grew 2% at actual rates and 4% at constant rates during the year ended December 31, 2013 . 8 Principally includes nutrition and anesthesia products. Nutrition products were previously reported with IV therapies in IV Therapies and anesthesia products were previously reported separately. 9 Principally includes sales from the pharmaceutical partnering business and pharmacy compounding services, which were previously reported with Global Injectables. Also includes revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies business after the February 2007 divestiture. BAXTER INTERNATIONAL INC. Franchise Sales by U.S. and International 1 Three-Month Periods Ending December 31, 2013 and 2012 (unaudited) ($ in millions) Q4 2013 Q4 2012 % Growth U.S. International Total U.S. International Total U.S. International Total BioScience Hemophilia $382 $590 $972 $336 $551 $887 14% 7% 10% BioTherapeutics 400 164 564 374 197 571 7% (17%) (1%) BioSurgery 109 85 194 102 78 180 7% 9% 8% Vaccines - 46 46 13 36 49 - % 28% (6%) Total BioScience $891 $885 $1,776 $825 $862 $1,687 8% 3% 5% Medical Products Fluid Systems $435 $384 $819 $380 $395 $775 14% (3%) 6% Renal 2 178 921 1,099 109 566 675 63% 63% 63% Specialty Pharmaceuticals 176 231 407 171 205 376 3% 13% 8% BioPharma Solutions 101 166 267 87 153 240 16% 8% 11% Total Medical Products 2 $890 $1,702 $2,592 $747 $1,319 $2,066 19% 29% 25% Total Baxter 2 $1,781 $2,587 $4,368 $1,572 $2,181 $3,753 13% 19% 16% 1 Effective January 1, 2013 , Baxter has transitioned to a commercial franchise structure for reporting net sales. Prior period net sales have been reclassified to reflect the new commercial franchise structure. Refer to page 18 for additional details. 2 Includes Gambro net sales of $413 million in the fourth quarter of 2013. Renal sales excluding Gambro grew 2% at actual rates and 5% at constant rates during the fourth quarter of 2013. Medical Products net sales excluding Gambro grew at 5% at actual rates and 7% at constant rates during the fourth quarter of 2013. Total Baxter net sales grew at 5% at actual rates and 6% at constant rates during the fourth quarter of 2013. Baxter International Inc. Media Contact: Deborah Spak , (224) 948-2349 or Investor Contacts: Mary Kay Ladone , (224) 948-3371 Clare Trachtman , (224) 948-3085 Source: Baxter International Inc.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Business Wire


Story Tools